Andrea Jiménez
University of Chile
24 Papers
58 Citations
Andrea Jiménez is an academic researcher from University of Chile. The author has contributed to research in topics: Cubic graph & Ising model. The author has an hindex of 6, co-authored 21 publications. Previous affiliations of Andrea Jiménez include University of São Paulo & Valparaiso University.
Chat about Author
Papers
Maximum number of sum-free colorings in finite abelian groups
Hiệp Hàn,Andrea Jiménez +1 more
TL;DR: In this article, the authors investigated the maximum number of sum-free r-colorings admitted by subsets of a finite abelian group G, and showed a close relationship between κr,G and largest sum free sets of G.
17
•Journal Article
On path-cycle decompositions of triangle-free graphs
TL;DR: In this paper, the authors study conditions for the existence of length-constrained path-cycle decompositions, i.e., partitions of the edge set of a graph into paths and cycles of a given minimum length.
Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management.
Rocio Sedano,Daniel Cabrera,Andrea Jiménez,Christopher Ma,Vipul Jairath,Marco Arrese,Juan Pablo Arab +6 more
TL;DR: The use of immune checkpoint inhibitors (ICI) has been successful for cancer types that do not respond well to conventional chemotherapy, showing clinical benefit in various advanced and metastatic cancers and supporting the promise of cancer immunotherapy as discussed by the authors .
10
On path-cycle decompositions of triangle-free graphs
TL;DR: The characterization of the class of all triangle-free graphs with odd distance at least $3$ that admit a path-cycle decomposition with elements of length at least £4 follows that Gallai's conjecture on path decomposition holds in a broad class of sparse graphs.
8
Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management
Rocio Sedano,Daniel Cabrera,Andrea Jiménez,Christopher Ma,Vipul Jairath,Marco Arrese,Juan Pablo Arab +6 more
TL;DR: The use of immune checkpoint inhibitors (ICI) has been successful for cancer types that do not respond well to conventional chemotherapy, showing clinical benefit in various advanced and metastatic cancers and supporting the promise of cancer immunotherapy as mentioned in this paper .
8